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Abstract
Adeno-associated virus (AAV) has been isolated from numerous vertebrate species
since 1966. Besides its wide and promiscuous tropism, AAV infection does not re‐
sult in considerable toxicity or pathogenicity and is capable of achieving adequate
and long-term levels of gene transfer, especially following generation of the AAV
recombinant variant: rAAV. Due to these properties, rAAV has gained special at‐
tention as a viral vector for gene therapy in the last decade. Currently, there are 130
clinical trials taking place worldwide for several diseases testing the safety and effi‐
cacy profiles of rAAV. During preclinical and clinical studies, several challenges
have arisen in terms of reaching the full therapeutic potential of rAAV, such as effi‐
cient delivery of the virus in a targeted and specific manner to a desired tissue. Im‐
portantly, the development of immune responses towards the viral capsids poses
an obstacle to rAAV applicability in the clinical setting. Numerous approaches have
been developed in order to tailor an optimized therapeutic virus for treating specif‐
ic diseases, including the use of different AAV serotypes or the creation of recombi‐
nant capsid variants with distinctive transduction and immunological profiles. This
chapter reviews current information on rAAV clinical trials and the potential for
combining rAAV platform with other technologies, such as induced pluripotent
cells and gene editing.
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1. Introduction
Gene therapy is currently one of the most promising technologies for the treatment and/or cure
of several genetic diseases. Furthermore, it has the potential to battle inherited disorders as
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well as acquired diseases. By inducing modification of the gene pool, gene therapy aims to
permanently and non-invasively treat the disease. Among the gene modifications that the
therapy allows, a gene could be added, by direct introduction of a gene copy, silenced, by
administering shRNA or siRNA, or removed, by the ZFN technology. Therefore, the spectrum
of diseases that could potentially benefit from this technology is expanding.
Even though the idea of gene transfer has been pursued for decades using an array of diverse
delivery approaches, several setbacks hampered its success for some time. In 1999, the death
of Jesse Gelsinger after receiving an adenoviral-based gene therapy for the treatment of severe
combined immunodeficiency disorder forced the halt on gene therapy progress [1]. Following
this tragic incident, a more serious regulatory scrutiny was established and the use of alter‐
native viral and nonviral vectors was investigated. Among viral platforms for gene delivery,
adeno-associated virus (AAV) emerged in 1965 and has attracted much attention since then
because the virus is not pathogenic, does not induce significant immune response and/or
toxicity to humans while it allows long-term transgene expression.
2. Emergence of rAAV as a therapeutic platform
Adeno-associated virus was first discovered in 1965 as a contamination of rhesus monkey
kidney cell cultures that were infected with adenovirus stocks [2]. Initially, the virus was called
defective as it was incapable of self-replicating in the absence of a helper virus, adenovirus or
herpesvirus. Later, it was classified as a member of the Parvovirus family, genus Dependovi‐
rus.
Further investigation determined that it is a small virus (approximately 20 nm) composed of
an icosahedral protein capsid, which contains single-stranded DNA of 4.7 kb. The viral genome
is flanked at each end by inverted terminal repeats sequences of 145 bp called ITRs. These
sequences self-assemble into hairpin structures, generating a double-stranded sequence,
which serves as a template for replication. The viral genome encodes for two proteins: Rep
and Cap. Rep is required for single-stranded DNA replication and packaging. Cap is necessary
to form the viral capsid and transduce cells efficiently.
AAV has never been associated with a disease or pathology [3]. Furthermore, due to the
homology between the Rep-binding element present on the ITR, and the rAAVS1 sequence
found on human chromosome 19, the viral genome can result in integration into the human
genome [4]. This last feature is important because it shows that the virus can facilitate long-
term expression of the viral genome. Additionally, specific integration of AAV in a defined
locus minimizes the risks of mutagenesis due to random insertions, as other vectors do.
However, several genetic modifications of AAV have been performed in order to guarantee
further safety for its translation into the clinic. First, the gene required for viral replication,
called Rep, and the element required for site-specific integration were eliminated from the
AAV genome. Therefore, this AAV variant, called recombinant vector (rAAV), will exist in an
extrachromosomal state with very low integration efficiency into the genomic DNA, reducing
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the possibility of inducing random mutagenesis. Second, packaging of the rAAV genomic
DNA was modified, incorporating a self-complementary rAAV genome rather than a single-
stranded DNA genome [5]. Self-complementary virus differentiates from the recombinant
virus in its ability to refold into double-stranded DNA, bypassing the synthesis of the second
strand. This substitution has the advantage of reducing the lag time prior to transgene
expression and consequently, increasing the biological efficiency of gene delivery. However,
it significantly reduces the size of the transgene that could be inserted into the rAAV genome,
from 5 kb to 3 kb. Third, several capsid serotypes that carry the rAAV genome have been
identified and isolated.
3. AAV capsid serotypes
Even though serotype 2 has been more extensively used and studied, other capsids are gaining
more interest. The existence of a variety of serotypes makes rAAV gene therapy more attractive
as they differ in infectivity rates and tissue specificity. For instance, a biodistribution analysis
of different AAV capsid serotypes carrying the same luciferase reporter gene showed a broad
dissemination of the virus in the mouse following intravenous administration [6]. In an attempt
to study phylogenetic relationships among serotypes 1 to 12, their capsid amino acid sequences
(NCBI reference sequences: NP_049542.1, YP_680426.1, NP_043941.1, NP_044927.1,
YP_068409.1, AAB95450.1, YP_077178.1, YP_077180.1, AAS99264.1, AY631965.1, AY631966.1
and AX753364.1) were aligned using ClustalOmega [7] and JalView, version 2.8.2 (Figure 1).
According to the degree of similarity that a residue has with the consensus residue for each
column, a certain color is given. Intensive blue corresponds to more than 80% agreement, light
blue to agreement between 60% and 80%, light grey to agreement between 40% and 60% and
white for agreement lower or equal to 40%. Below the alignment, conservation, quality and
consensus information are provided. Conservation graphic highlights alignment regions
where physicochemical properties are conserved. The more intense the color, the more
conserved the physicochemical property is in the column. Alignment quality indicates the
likelihood of observing substitutions in a particular amino acidic position. Finally, the residue
consensus provides the most common residues and their percentage for each column of the
alignment.
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Figure 1. Multi-sequence alignment of AAV serotypes from 1-12 using ClustalOmega and JalView software.
Following the multisequence alignment, the percentage of sequence homology was deter‐
mined by performing BLAST alignments of dual AAV sequences at the time (Figure 2a).
Furthermore, the phylogenetic relationships among these AAV serotypes were determined by
creating a neighbor-joining tree (Figure 2b), which uses the percent identity [8].
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Figure 2. A, Blast alignment of dual combination of AAV serotypes to determine percentage of homology. B, Phyloge‐
netic tree to determine phylogenetic relationships among the studied serotypes.
This tree shows that serotype AAV5 has the most divergent amino acid capsid sequence,
sharing between 53% and 59% homology with the rest of the human serotypes that have been
discovered so far (highlighted in orange). AAV4 also shows a considerable degree of diver‐
gence, when comparing sequences of AAV1 to 9 (between 53% and 64%). However, AAV4
shares a more recent common ancestor with serotypes 11 and 12. Furthermore, AAV1 and
AAV6 share 99% homology, being the closest AAV serotypes in sequence. The most common
AAV serotype, AAV2, is closer in amino acid sequence to all the AAV serotypes, especially
AAV3, but greatly differs from serotypes AAV5, AAV4 and therefore, AAV11 and AAV12.
Serotypes AAV8 and AAV10 are also very close between each other, sharing 93% amino acid
sequence homology. These differences in sequences were observed in other studies, not only
when analyzing the sequence similarities but also when studying antigenic reactivities [9].
Remarkably, the variabilities in amino acidic sequences were mainly localized in the looped-
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out domains that are exposed to the surface of the capsid, rather than evenly distributed along
the capsid protein sequence [10]. More interesting, Gao et al. compared phylogenies from
human and nonhuman primate AAV serotypes. They observed that human AAV4 and AAV5
serotypes were the most divergent, and after they emerged, the rest of the viruses were
clustered in groups that included human serotypes (AAV1, AAV6, AAV2, AAV3 and AAV9),
exclusive rhesus serotypes (AAV7) or a combination of both (AAV8). Considering that human
AAV serotypes share a high similarity in sequences with nonhuman AAV serotypes, they are
both well disseminated and are able to cross species barriers. Therefore, there is a possibility
that AAV from nonhuman primates could be used for treating human diseases. This is the case
of AAVrh10, a serotype isolated from rhesus macaques. This virus was found to be signifi‐
cantly more efficient in transducing neurons from different areas in a healthy dog brain as
compared with AAV1 or AAV5, but to a similar extent with AAV9 [11]. More importantly, the
rhesus serotype is currently being tested for safety and efficacy in the clinic for the treatment
of CNS diseases, such as Battens (NCT01414985 and NCT01161576, clinicaltrials.gov) and MLD
(NCT01801709, clinicaltrials.gov). Additionally, a new study is planning to test the safety of
this virus for delivering human alpha 1-antitrypsin cDNA to individuals with alpha 1-
antitrypsin deficiency (NCT02168686, clinicaltrials.gov); although they are not yet recruiting
patients.
Figure 3. Biodistribution of AAV serotypes 1–9 in mouse.
According to the biodistribution study of AAV following tail vein injection into the mouse,
AAV9 has the broadest tissue tropism, demonstrating robust transduction of all tested tissues
other than the testes [6] (Figure 3). Moreover, it is the most efficient in reaching the brain, followed
by AAV8. On the other hand, AAV7 showed strong tropism for the liver and to a lesser extent
for the muscle. Meanwhile, AAV6 had more preference for the heart, in comparison to liver,
lung and muscle. AAV4 was found in higher viral copies in the lung, followed by the heart. The
rest of the serotypes transduced the selected tissues with lower efficiencies. AAV1 and AAV2
were more prone to reach the liver. In terms of infection kinetics, AAV7 and AAV9 were the
fastest in targeting the tissue and showing expression of the reporter gene, luciferase. Mean‐
while, AAV3 and AAV4 were the slowest ones. Additionally, among all the serotypes, AAV2,
3, 4 and 5 showed the lowest transduction efficiency.
The first AAV primary receptor that was identified was heparin sulfate proteoglycan (HSPG).
It is the receptor that AAV2 and AAV3 bind when infecting cells (Figure 4). Even though AAV6
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was shown to have moderate binding affinity for heparin, it does not have the two residues
R585 and R588, that participate in AAV2 binding to HSPG. On the other hand, while sequence
alignment comparison between AAV1 and AAV6 capsids revealed only a six–amino acid
difference, AAV1 is not able to bind heparin. Mutagenesis analysis revealed that amino acid
531 was responsible for providing the heparin binding ability to AAV6 and not to AAV1 [12].
Furthermore, AAV1 binds both α2–3 and α2–6 N-linked sialic acid (SIA), same as AAV6.
Interestingly, AAV5 also binds α2–3 SIA, although it only shares ~40% homology with capsid
serotypes AAV1 and AAV6. Crystallography studies of AAV5 showed differences in the
surface loop regions, specifically smaller HI loop and larger VR-VII loop, which are located
on the depression wall at the icosahedral 2-fold axis and determine receptor binding, tissue
transduction efficiency and antigenic reactivity [13].
AAV4 capsid serotype follows AAV5 in terms of low sequence similarity with the rest of the
serotypes and between themselves (53% sequence homology). A study, in which sialic acids
were removed from cell surfaces, by neuraminidase treatment, showed that both viruses
require SIA for infectivity [14]. However, when cellular glycosylation was inhibited, only
treatment with O-linked inhibitor decreased binding of AAV4 to cultured cells. Meanwhile,
treatment with N-linked inhibitors of glycosylation blocked AAV5 binding to the cell surface.
Resialylation experiments with neuraminidase-treated red blood cells further confirmed that
AAV4 binding to SIA is through α2–3 O-linkage, rather than through α2–6 N linkage, which
is the interaction that AAV5 establishes for the initial infection of a cell.
Still, currently, receptors for AAV7 and AAV8 are unknown. Glycan binding analysis on
microarrays revealed that AAV7 and AAV8 did not bind to any of the glycans that commonly
bind serotypes AAV1–6 [15]. However, similarly to AAV2 and AAV3, AAV8 and AAV9
interact with the 37/67 kDa laminin receptor (LamR), as a secondary receptor, for efficient
internalization and transduction [16]. LamR participates in interactions of extracellular
laminin1 with proteases and with the cell; therefore, it is widely distributed among human
tissues. Even though, AAV2, 3, 8 and 9 serotypes mediate direct tissue transduction via
interaction with the LamR molecule, they significantly differ in their tissue tropism. AAV8 and
9 are able to infect a broader spectrum of tissues, even the brain, compared to serotypes AAV2
and AAV3. This result suggests that the primary receptor or the combination of both receptors
is required for viral biodistribution. At the UNC gene therapy center, the Asokan laboratory
was able to identify that N-linked glycans with terminal galactosyl residues are involved in
AAV9 tissue binding and transduction [17]. The high abundance of these glycans in various
animal tissues could explain the broad tropism observed after AAV9 systemic administration.
Lastly, the brain is one of the most difficult tissues that AAV can access and infect following
systemic administration. The presence of a mature blood–brain barrier constitutes a physical
barrier to potential harmful molecules and infectious pathogens. Therefore, most of the AAV
serotypes are not able to access the brain without direct intraparenchymal administration.
However, AAV9 and AAV8 (to a lesser extent), have the capability to reach the brain following
intravenous administration to neonatal or adult mice [18].
Furthermore, the rhesus serotypes AAV10 and AAV11 were found to be sequence homolo‐
gous and structurally closest to the previously described serotypes AAV8 and AAV4, respec‐
tively [19].
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AAV12, which was isolated from a simian adenovirus stock, showed 74% homology with
AAV4 and 84% with AAVrh11. However, it does not bind SIA and appears to have strong
affinity for human cancer cell lines [20].
  Primary 
 receptor 
   
Secondary 
 receptor 
rAAV1 rAAV2 rAAV9 rAAV7 rAAV3 rAAV8 rAAV4 rAAV5 rAAV6 
 
 
Figure 4. Primary and secondary receptors used for AAV serotypes from 1 to 9 to infect and transduce cell types.
HSPG, heparin sulfate proteoglycan; FGFR1 fibroblast growth factor receptor 1; PDGFRB, platelet-derived growth fac‐
tor receptor beta; HGFR, met/hepatocyte growth factor receptor; EGFR, epidermal growth factor receptor; LamR, lami‐
nin receptor.
4. Preclinical studies of rAAV in large animal models
In an effort to translate the rAAV gene therapy to the clinic, preclinical studies for safety,
efficient rAAV dosing and capsid transduction, transgene expression and immune responses
towards the new transgene and/or the rAAV capsid were performed. In Figure 5, we summa‐
rize which serotype has been evaluated for targeting a certain disease in a large animal model,
such as nonhuman primate, pig, cat, dog, rabbit and sheep. However, this section will be
focused on preclinical studies using large animals for the treatment of hemophilia.
Figure 5. Diseases treated in large animal models with different AAV serotypes
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5. rAAV targeting the liver for hemophilia treatment
Even though rAAV therapies for treating hemophilia in mice produced successful results, their
translation into large animals, such as a dog or nonhuman primate, was not straightforward
[21]. The vector efficacy does not completely follow a dose–response correlation in large
animals, and it is drastically affected in the presence of an immunological response towards
the viral capsids. Furthermore, in both mice and dogs, there is no direct correlation between
the transgene copy numbers and the expression of the foreign protein. However, treatment of
a large animal with the therapy was promising as FIX is a secreted protein and only 1%–2%
normal factor IX levels is enough to correct the disease [21].
Therapies for hemophilia B were studied using different routes of rAAV gene therapy
administration. Initially, intramuscular delivery of rAAV-CMV-cFIX to hemophilic dogs was
pursued. A single administration of the virus generated a therapeutic FIX level in a dose-
dependent manner [22]. However, the amount of antibody formation, and therefore, the
success of the therapy, directly correlated with the increase in rAAV dose [23]. Considering
that FIX is produced within the liver, delivery of the virus through the portal vein was also
attempted. Several steps were performed in order to optimize the vector, such as the addition
of a liver specific promoter, and testing different doses to determine the optimum for allowing
normal levels of FIX in the dog through this route [24–26]. Mount et al. observed sustained
levels of FIX between 4% and 12% at doses between 1.2 × 1012 and 3.4 × 1012 vg/kg for over 17
months in three out of four dogs [26]. The fourth dog experienced a transient correction of FIX
levels for four weeks but eventually developed neutralizing antibodies against the transgene.
In another study, delivery of a hyperfunctional FIX through rAAV-mediated transfer to the
liver in hemophilic dogs resulted in 25% and 300% FIX levels for 1 × 1012 and 3 × 1012 vg/kg
doses, respectively [27].
Studies performed with nonhuman primates generated variable outcomes, from no detection
to detection up to 10% of FIX in the serum. Failure of the gene therapy was attributed to the
preexistence of neutralizing antibodies against the transgene [28, 29]. However, direct
administration of the rAAV vector to the liver induced some tolerance to the transgene [27,
28]. Another strategy to overcome the success of the therapy due to the presence of neutralizing
antibodies consists of administration of the therapy to an early age of the animal, presumably
because the immune system is not completely developed [30].
A comparison study of different administration routes for rAAV-FIX delivery on mice revealed
that the same dose allowed 3-fold more transgene expression following intrahepatic rather
than intramuscular or intravenous delivery [31]. Therefore, it seems that transgene delivery
via rAAV virus is more successful when using the liver-directed gene route. When intrahepatic
therapy was administered to dogs who suffered from hemophilia A, rAAV8 carrying the
canine factor VII cDNA showed long-term correction of the phenotype, with no spontaneous
bleeding episodes, no toxicity and no development of inhibitory antibodies towards the viral
vector or the transgene [32]. Similarly, liver-directed rAAV-FIX therapy to dogs suffering from
hemophilia B, significantly increased FIX activity to 4%–10% and remained stable for more
than eight years [33]. However, direct injection of the virus to the muscle resulted in unde‐
tectable FIX levels in the dog due to the onset of an immune response.
Gene Therapy - Principles and Challenges128
6. Clinical trials using rAAV technology
Among the clinical trials reported in clinicaltrials.gov website, which cites ongoing studies all
over the world, the United States is still the leading country conducting clinical trials with
rAAV gene therapy. In 2010, 47 studies out of 70 were performed in the United States and in
2015, 44 total studies out of 66 have been sponsored by the same country. Since the first
registered trial in 2004, a total of 14 studies have been completed, and three terminated
prematurely. Furthermore, there are clinical trials in all phases as well as for traditional, not
traditional and even recombinant serotypes (Figure 6). Worldwide, there are a total of more
than 130 clinical trials testing rAAV gene therapy for the treatment of diseases (http://
www.abedia.com/wiley/vectors.php).
Figure 6. Statistics showing the clinical trials performed with rAAV gene therapy until 2015 according to clinicaltri‐
als.gov. A, Classified according to the clinical phase. B, Classified according to the rAAV serotype used in the study.
7. rAAV serotypes used in clinical trials
Traditionally, the most common serotype used in clinical trials is AAV2. In 2010, sixty-two
clinical trials were performed with rAAV2 vector; meanwhile, the number was reduced to
thirty-six, almost half, in 2015 (89% vs. 54%) (Figure 7A). In addition, in 2010, three studies
were performed with rAAV1, which increased to 10 in 2015 (4% vs 16%). Interestingly, more
uncommon serotypes are acquiring an interest among the scientific community and the
spectrum of serotypes being tested is increasing. Five years ago, five out of seventy clinical
trials used serotypes other than rAAV1 and rAAV2. On the contrary, now in 2015, eighteen
out of the current forty-nine trials are reported in clinicaltrials.org website (7% vs. 37%). For
instance, the number of studies using serotype rAAV8 increased from two to seven in a five-
year frame (Figure 7B).
The same results were found with the rhesus serotype rAAVrh10; initially, there was one study
testing the virus; however, in 2015, six studies have taken place. To note, another rhesus rAAV
serotype is being examined: rh74 for duchene muscular dystrophin. Serotypes rAAV5 and
AAV Biology, Infectivity and Therapeutic Use from Bench to Clinic
http://dx.doi.org/10.5772/61988
129
rAAV9 also were introduced into the list of rAAV viruses in clinical trials. Similarly, phase I/
II rAAV10 trial for Sanfilippo type A syndrome started in 2011 and finished in 2014.
As Figure 8A shows, in 2010 a high percentage of the rAAV therapies were in phase I (62%)
and a small percentage of the studies (17%) were testing phase I and II on the same trial. In
2015, the number of studies in phase I exclusively was reduced by 20%, compared to studies
performed in 2010, and that extra 20% is testing safety and efficacy at the same time (phase I
and II, 37%), probably due to the expensive costs of conducting a clinical trial.
Furthermore, the number of studies that were in phase III was reduced, as the therapies started
to reach the market. For instance, in October 2012, Glybera became the first rAAV gene therapy
to obtain marketing authorization from the European Commission.
Since their discovery in the 1960s as small DNA viruses contaminating cultures of simian and
human adenoviruses [2, 34], AAV vectors have been tested in more than a hundred clinical
trials. Completed and ongoing trials have consistently confirmed that rAAV vector delivery
is safe, well tolerated by humans and efficient in transferring the therapeutic gene. Figure 8B
summarizes the spectrum of diseases that have been tested with rAAV gene therapy in 2010
A 
B 
Figure 7. Statistics showing the clinical trials performed with rAAV gene therapy in 2010 and in 2015. A, Classified
according to the use of traditional serotypes rAAV2 and rAAV1. B, Classified according the use of no traditional rAAV
serotype.
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and 2015. The statistics show that neurological and ocular diseases are gaining more interest,
probably because they both constitute immunological privileged tissues. Figure 9 summarizes
the diseases that are being treated with AAV technology, according to the serotype.
As an ocular AAV therapy, two clinical trials have tested rAAV2 therapy for the correction of
Leber congenital amaurosis, an autosomal recessive disease that results in blindness. Specifi‐
cally, patients who participated in these studies received the normal copy of the retinal pigment
epithelium-specific 65 (RPE65) gene to correct for the deficient gene. One trial was performed
in London and consisted of delivering the gene, the expression of which was driven by an
endogenous RPE65 promoter, to adolescent patients [35]. On the other hand, the study
performed in Philadelphia delivered the gene in the context of a constitutive promoter, to
pediatric and adult patients [36, 37]. Pediatric patients treated in the US resulted in the best
improvement in vision, followed by American adults. However, one out of three British
patients manifested a visual function improvement. Another trial, sponsored by the University
of Pennsylvania, conducted an open-label, dose-escalation phase I study on 15 patients aged
between 11 and 30 years. The study examined safety and efficacy. Results showed no toxicity
due to the therapy, although some adverse events were observed from the surgery procedure.
A 
B 
Figure 8. Statistics showing the clinical trials performed with rAAV gene therapy in 2010 and in 2015. A, Classified
according to clinical phase. B, Classified according the treated disease.
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Furthermore, visual function was improved in the 15 patients with a variable degree [38].
However, between 9 and 12 months of gene therapy administration, four of the fifteen patients
experienced new pseudo-foveas in the retinal regions, for up to six years [39].
The company Sparks, which is sponsoring the studies in the US, is testing the technology
developed at the Children’s Hospital of Philadelphia in a phase 3 trial and expects to announce
their results in 2015. If the results are promising, it could be the next rAAV gene therapy
product to be launched in the market.
Among the brain diseases, Parkinson’s treatment was attempted with rAAV gene therapy
delivering different transgenes. Administration of glutamic acid decarboxylase (GAD) via
rAAV2 produced modest efficacy improvements. Patients were injected with rAAV2 coding
for GAD65 and GAD67 in the center of the subthalamic nucleus [40]. Six months following the
injection, the unified Parkinson’s disease rating scale decreased by 8.1 points, compared with
a reduction of 4.7 points that the sham operation group evidenced. Six months later, clinical
improvements were still being noticed. However, the results were modest and the protocol
had some deviations. For instance, patients who showed no benefit on the primary endpoint
were eliminated from the statistical analysis, arguing that the injections were off-target [41].
Administration of aromatic L-amino acid decarboxylase (AADC) gene was tested on a phase
I trial that consisted of the treatment of 15 patients with moderate disease [42, 43]. The trial,
sponsored by Genzyme, observed only a modest efficacy, results that were confirmed by a
second study performed in Japan [44]. Similarly, phase I and II trials with the rAAV2-neurturin
(CERE-120) vector from Ceregene failed to show statistically significant improvement in the
rAAV-treated group compared with the group that received the sham surgery [45, 46]. As a
conclusion of all these different trials, the technology is safe and is promising. However,
Figure 9. Diseases currently being tested in clinical trials with different rAAV serotypes.
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efficacy is modest and does not justify the procedure. Further improvements could be
performed, such as modification of the delivery vector, as rAAV1 and rAAV5 are more efficient
in transducing the substantia nigra and caudate nucleus than rAAV2. Furthermore, viral dose
increase should be considered [41]. On the other hand, long-term improvements were
observed during the treatment of Canavan disease [47]. Patients were administered rAAV2
carrying the aspartoaculase gene directly to the brain parenchyma. Five years posttreatment,
patients presented slower progression of brain atrophy, fewer frequent seizures and general
clinical stabilization. Importantly, no serious adverse events were observed, even when one
of the patients was a 3-month-old infant [48].
In a trial testing gene therapy for cardiac disease, patients received different doses (low,
medium or high) of the sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) gene via rAAV1 [49].
Six months following the percutaneous intracoronary infusion of the virus, several clinical
parameters, such as walk test, peak maximum oxygen consumption, left ventricular end-
systolic volume, cardiovascular events and time to clinical events were stabilized or even
improved. Currently, a phase 2b trial is ongoing, which would test a larger patient population
(NCT01643330).
The first clinical trial for rAAV gene therapy that reached the market was the product Glybera®
(alipogene tiparvovec), an rAAV1 vector delivering a lipoprotein lipase variant (LPLS447X)
for the treatment of lipoprotein lipase deficiency (LPLD). Lipoprotein lipase is a secreted
enzyme produced by the skeletal muscle and adipose tissue. Its function involves the metab‐
olism of triglycerides, chylomicrons and very low-density lipoproteins. Three clinical trials
showed that Glybera is safe and efficient for the treatment of LPLD. In the first trial, two doses
of rAAV1_LPLS447X were studied: low and high [50]. Nevertheless, none of the doses resulted
in a permanent decrease in triglyceride levels. There was only a transient reduction, possibly
due to the development of an immune response. The second clinical trial received the therapy
in combination with an immunosuppressive regimen [51]. Similar to the first clinical trial, the
effects of the therapy were only transient in the beginning. However, improvements were
observed after two years posttreatment, such as tolerance to certain foods, changes in the blood
lipid content and a decreased frequency of pancreatitis. Due to a discrepancy in the clinical
outcomes and plasma triglycerides levels, a third trial was set with predetermined parameters
to measure, as incidence frequency of abdominal pain, pancreatitis and chylomicron plasma
clearance [52]. Five newly treated patients evidenced a reduction of the parameters and an
improved quality of life for two years following administration.
These results, combined with the ones obtained from the reanalysis of 22 of the 27 previously
treated patients, confirmed the therapeutic benefits of therapy and granted its approval to the
market by the European Commission in November 2012.
8. Clinical trials for hemophilia B treatment
Hemophilia B is an X-linked recessive disorder, which originated from mutations within the
gene that encodes the coagulation factor IX. Therefore, patients whose functional FIX levels
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are 1% of normal levels will bleed into the joint and muscle tissues. Bleeding in the brain could
result in fatal death. If FIX levels are between 1% and 5%, the individual will experience a
reduced number of bleeding incidents and a moderate phenotype of the disease. Any FIX levels
above 5% will allow the person to have a normal life [53]. The only available treatment is
protein replacement therapy, which requires regular intravenous injections and is expensive.
Therefore, novel and permanent therapies/treatments are urgent. rAAV gene therapy cur‐
rently constitutes a promising approach for the treatment of several diseases, including
hemophilia B.
Based on animal studies that were described in the previous section, four clinical trials have
been initiated. The first study administered rAAV carrying FIX gene into three patients by
intramuscular injection. Despite the presence of preexistent high titer of neutralizing antibod‐
ies against capsid rAAV, strong transgene expression was observed in the muscle, even after
10 months of injection. However, levels of factor IX in circulation were less than 1–2% in most
cases, even at the highest tested dose. Toxicity was not observed [54, 55].
The second trial conducted by the University of Pennsylvania infused the virus through the
hepatic artery into seven patients. The rational in this protocol considered that FIX is a secreted
protein and once it is produced and reaches the bloodstream; it can be distributed throughout
the body.
Even though levels of FIX resulted higher than 5% after injecting an intermediate or high viral
dose, the therapeutic effect was only transient (up to eight weeks), due to the development of
a strong cytotoxic T response, which destroyed the transfected hepatocytes and thus hampered
the production of FIX [56].
The third trial was designed in order to increase FIX expression production as well as to
circumvent the possibility of a humoral response that could interfere with the success of the
therapy [57]. To reach the first goal, they developed a codon optimized FIX gene that also
delivered the gene in the context of self-complementary rAAV, which provides substantially
higher levels of transgene expression rather than delivering the WT gene with single-stranded
rAAV. In order to reduce antibody neutralization, the viral genome cassette was packed in
rAAV8 capsid, as it has lower seroprevalence in humans and a high tropism for the liver. The
virus was administered directly in the peripheral vein in six patients, and all of them developed
1–6% levels of factor IX expression in the first four months as well as for at least three years.
There was no modification on the levels of neutralizing antibodies. However, transient
elevations in serum liver enzymes, possibly as a result of a cellular immune response to the
rAAV8 capsid, were observed in the three patients who received the high viral dose.
Recently, Baxter’s laboratories launched a clinical trial to test the safety and efficacy of a self-
complimentary rAAV8 vector carrying a mutant FIX sequence (BAX 335), created and
preclinically tested at the UNC gene therapy center [58]. The FIX sequence had a single amino
acid change at position 338, which substantially increased the levels of circulating FIX protein.
A more effective rAAV delivery vehicle allowed the administration of lower viral doses with
the same efficacy as previous tested virus, but without the associated toxicity. In this trial,
sixteen adult patients were treated in different centers around the US. Updates on the trial
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were presented at the 8th Annual Congress of the European Association for Haemophilia and
Allied Disorders this year in Finland. At this time, patients who received the highest dose did
not develop inhibitory antibodies, reached FIX protein activity of 10% or more and did not
manifest bleeding events. However, one of the patients experienced elevated levels of liver
enzymes probably due to an immune response.
Nowadays, investigators are still developing better strategies to overcome the immunological
response; currently, there are six trials evaluating safety and efficacy, including BAX 335.
9. rAAV and gene editing technology
Several genome editing tools have emerged recently in an attempt to correct the genetic
cause(s) of a disease. These technologies rely on two components: a sequence-specific DNA-
binding domain and a nuclease [59]. The procedure consists of several steps: (1) recognition
of a targeted DNA sequence, (2) double stranded cut and (3) stimulation of a cellular repair
mechanism to correct the DNA damage, which includes homologous recombination [60].
This technology allows for modifying a coding sequence, the epigenome, transcriptional
activator/repressor as well as a regulatory element such as transcription factors, recombinases,
transposases, and more. When targeting a particular gene, these technologies generate
deletions, insertions or mutations of the gene, which may be useful to elucidate the gene
function, or to generate cell lines with the null phenotype, or even to model a specific genetic
condition for its study. Three different systems are currently available: zinc-finger nucleases
(ZFN), TALEN nucleases and CRISPR/Cas9 [60].
Zinc-finger nucleases are a common type of DNA-binding motif found in eukaryotes and
therefore, in the human genome. Usually, the DNA binding domain in the zinc-finger nuclease
recognizes three base pairs in the DNA sequence. However, researchers have engineered the
domain in order to detect and bind any defined DNA sequence of 9 to 18 bps in length, allowing
the targeting of up to 68 billion bp of DNA [61].
Even though these technologies are very promising, an optimal delivery vehicle of the gene
editing system needs to be developed. rAAV has the potential to deliver nucleases in vitro and
in vivo and also has the potential to induce homologous recombination in the cell that infects,
further enhancing the homologous recombination efficiency by 1000-fold [62–64].
In 2011, High et al. showed the generation of a ZFN system capable of cleaving F9 intron 1 and
inducing homology-directed repair in the human hepatocyte Hep3B cell line. As proof of
principle, the system induced up to 17% stable integration of a novel restriction enzyme site
into the F9 locus. Furthermore, intraperitoneal administration of a ZFN system, which
specifically targets F9, via rAAV8 delivery, in conjunction with an rAAV8 vector carrying a
corrective F9 complementary DNA cassette into a humanized neonatal mouse model of
hemophilia B, resulted in 1%–3% specific targeting of mouse liver. However, this mouse at
two days old produced 2–3% normal F9 levels, enough amount to convert severe to mild
hemophilia [65]. In 2013, they tested the same technology in a young adult mouse (8–10 weeks
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old), in which hepatocyte proliferation is slow as the liver already reached its maturity [66]. In
theory, younger mice should show higher levels of gene correction, compared to older mice,
as mice age affects the rate of homologous recombination, which is essential for genome editing
to occur. In this publication, even though adult mice showed limited hepatocyte proliferation,
following AAV injection, mice experienced a 5-fold increase in FIX expression, compared to
the previous study. Moreover, when they tested the technology in even older mice, 7–8 months
old, FIX levels were extremely low. Investigators argue that the discrepancies in FIX levels
between neonate and adult mice could be attributable to the loss of rAAV vector genomes
during liver development and/or different promoter activity. Furthermore, when they
switched the use of homodimer nucleases to heterodimeric ZFN, nonespecific ZFN cleavage
was observed without the loss of FIX expression.
Additionally, ZFN technology is currently being investigated in clinical trials for the treatment
of HIV. Basically, the therapy consists of ex vivo permanent modification of patient T cells to
knock down the HIV entry receptor CCR5 and autologous administration of the recombinant
cells back to the patient. This clinical trial is sponsored by Sangamo Biosciences, the same
company that collaborated with D. High for the in vivo targeting of hemophilia B mouse with
rAAV-ZFN platform. In 2014, the company released an announcement for the first IND to test
ZFN genome-editing platform in hemophilia A patients.
Even though these studies performed by Dr. High’s laboratory and Sangamo Biosciences
showed potential for in vivo gene editing via rAAV delivery, especially for diseases which do
not allow ex vivo manipulation of target cells such as hemophilia B, the technology has several
issues to address before being considered efficient and safe for treating human patients. First
of all, we should consider all the challenges associated with rAAV delivery in vivo, such as
the development of a cytotoxic T cell and/or neutralizing antibody responses and exclusively
targeting of the tissue to correct with high efficiency. Furthermore, in order for this therapy to
work efficiently, each cell needs to receive the two viruses at the same time, a condition that
is possible but with a much lower probability to occur, and even if it takes place, the individual
would be exposed to higher doses of rAAV8, which enhance the probability of inducing an
immune response. Given that homologous recombination repair mainly takes place during
the S phase of the cell cycle, gene editing is limited to be successful only in young patients,
unless it is combined with molecules/drugs that boost cell division. Importantly, off-target
double-stranded DNA breaks pose the possibility of inducing vector integration and/or
undesired mutations and consequently, inducing oncogenesis, cell death and/or genetic
diseases. This last possible issue could be solved by using self-inactivating viruses. Finally, the
ZFN rAAV-mediated technology is still in the early phase of development, so far it has proven
its potential for permanently correcting monogenetic diseases. However, considering that (1)
rAAV gene therapy has shown great promise in the treatment of hemophilia B and (2) very
low levels of FIX are enough to prevent bleeding and allow the person to have a normal life,
in vivo gene editing technology seems too risky and unnecessary to pursue for the treatment
of hemophilia diseases.
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10. iPSC and rAAV
iPSC technologies have gained special interest since their discovery in 2006 by Takahashi
and  Yamanaka  [67].  The  generation  of  iPSC  has  several  applications.  One  of  the  most
important applications consists of the generation of: (1) pluripotent stem cells from a fully
differentiated patient cell or (2) a specific human cell that is scarce or not accessible to the
scientific population, from a healthy or diseased individual, following differentiation of the
pluripotent  stem  cell.  Moreover,  sometimes,  a  personalized  treatment  is  required  or  a
diverse population cell sample is needed for testing the efficacy of a therapeutic technolo‐
gy,  such  as  rAAV.  For  instance,  the  common  practice  is  to  reprogram  patient-derived
fibroblasts into a specific cell type that is affected by a disease. Some attempts have been
performed to reprogram fibroblasts of patients suffering from retinal diseases into iPSC and
finally differentiate the pluripotent stem cells into retinal pigment epithelial (RPE) cells that
manifest the diseased phenotype [68, 69]. Following the validation of iPSC and then RPE
cells, a panel of rAAV serotypes could be tested for their efficiency to transduce the cells
and the most effective ones could be chosen for delivering the healthy gene copy in order
to re-establish normal cellular phenotype [70].
Another approach for inducing iPSC development has been tried, but this time, using an
rAAV  system  rather  than  a  retrovirus.  IPSC  generated  by  Takahashi  and  Yamanaka’s
original protocol made use of retroviruses to deliver Oct3/4, Sox2, Klf4 and c-Myc. Even
though  the  approach  resulted  in  the  generation  of  pluripotent  stem  cells  from  mouse
embryonic or adult fibroblast cultures, still the efficiency was extremely low, the presence
of c-Myc oncogene significantly increased the incidence of tumorigenicity and the use of
retrovirus posed the threat of integration into the genome. Several new strategies have been
developed, including the use of rAAV [69, 71]. Considering the advantages of using rAAV
for gene delivery, such as long-term transgene expression for efficient reprogramming of
mature cells as well as safety and efficacy as a gene delivery vehicle in the clinic; research‐
ers have attempted their use in the reprogramming of fully differentiated fibroblasts as well
as  adipose-derived  mesenchymal  stem  cells.  However,  both  studies  observed  frequent
rAAV integration into the host genome of iPSC cells when the iPSC were generated from
nondividing cells. Integration events were independent of the rAAV vector, cell type and
amount of virus. Both studies concluded that there is a certain degree of incompatibility
between iPSC generation and the use of rAAV vectors, although reprogramming does not
require  an  integration  event.  Furthermore,  like  retrovirus-mediated cell  reprogramming,
rAAV-mediated  iPSC  generation  resulted  in  reprogramming  transgene  silencing,  which
affects  the quality of  the induced pluripotent stem cells  that  could be generated.  There‐
fore, if the integration events are tightly controlled, which is feasible, and if the epigenet‐
ic mechanisms of rAAV silencing are discovered, rAAV technology could result in a safer
mechanism for inducing pluripotent stem cells and consequently, increasing the chances of
being applicable to the clinic.
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